贾美群, 陈曾燕, 施玲燕, 赵斌, 吴霞, 吴银芳. IGF1信号通路IGF1 IGF1R及AKT在卵巢癌顺铂耐药中表达的研究[J]. 中国肿瘤临床, 2014, 41(5): 286-290. DOI: 10.3969/j.issn.1000-8179.20131238
引用本文: 贾美群, 陈曾燕, 施玲燕, 赵斌, 吴霞, 吴银芳. IGF1信号通路IGF1 IGF1R及AKT在卵巢癌顺铂耐药中表达的研究[J]. 中国肿瘤临床, 2014, 41(5): 286-290. DOI: 10.3969/j.issn.1000-8179.20131238
shu
JIA Meiqun, CHEN Zengyan, SHI Lingyan, ZHAO Bin, WU Xia, WU Yinfang. Key protein expressions in the insulin-like growth factor-1 signal pathway involved in the resistance of ovarian cancer to cisplatin[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2014, 41(5): 286-290. DOI: 10.3969/j.issn.1000-8179.20131238
Citation: JIA Meiqun, CHEN Zengyan, SHI Lingyan, ZHAO Bin, WU Xia, WU Yinfang. Key protein expressions in the insulin-like growth factor-1 signal pathway involved in the resistance of ovarian cancer to cisplatin[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2014, 41(5): 286-290. DOI: 10.3969/j.issn.1000-8179.20131238
shu

IGF1信号通路IGF1 IGF1R及AKT在卵巢癌顺铂耐药中表达的研究

Key protein expressions in the insulin-like growth factor-1 signal pathway involved in the resistance of ovarian cancer to cisplatin

    摘要
  • 摘要:
      目的  检测IGF信号通路关键蛋白IGF1、IGF1R及AKT在卵巢癌患者血清及组织中的表达。
      方法  ATP-TCA法对卵巢癌标本进行药敏试验，ELISA法检测顺铂耐药和敏感组患者血清中IGF1、IGF1R及P-AKT的表达，免疫组织化学检测卵巢癌组织中IGF1、IGF1R、Akt的表达。自患者完成化疗出院后每个月复查CA125，如CA125有异常则行影像学检查，随访时间1年。
      结果  IGF1、IGF1R及AKT在卵巢癌顺铂耐药组的表达显著高于敏感组（P=0.000 1），免疫组织化学结果显示顺铂耐药组和敏感组IGF1、IGF1R及AKT的表达相比较差异有统计学意义（P＜0.05）。随访顺铂敏感组24例中有18例患者超过1年CA125处于正常值；6例患者超过半年CA125处于正常值；耐药组中有16例患者化疗结束后半年内CA125上升高于正常值，彩超或MRI检查提示有复发病灶。
      结论  IGF信号通路关键蛋白可能参与卵巢癌顺铂耐药，IGF1可能作为卵巢癌靶向治疗的新靶点。

     

    Abstract:
      Objective  This study aimed to detect the expression levels of the key proteins involved in the insulin-like growth factor signaling pathway of patients with ovarian cancer. These proteins include insulin-like growth factor-1 (IGF1), insulin-like growth factor-1 receptor (IGF1R), and protein kinase B (AKT).
      Methods  Ovarian cancer tissues were subjected to drug resistance tests using the ATP-TCA method. IGF1, IGF1R, AKT, and multidrug resistance protein2 (MRP2) expressions were detected in the sera of patients with ovarian cancer by conducting enzyme-linked immunosorbent assay. IGF1, IGF1R, and AKT protein expressions were detected in the surgical specimens by immunohistochemistry. Patients were instructed to monitor their cancer antigen 125 (CA125) levels monthly from the date a patient was discharged to the last day of chemotherapy (or until chemotherapy was completed). A color Doppler ultrasound, CT, or MRI scan was required if CA125 value is abnormal. The total follow-up time was one year.
      Results  IGF1, IGF1R, and AKT expressions were significantly higher in the cisplatin-resistant group than in the cisplatin-sensitive group (P =0.000 1). Immunohistochemical results showed that IGF1, IGF1R, and AKT expressions were significantly higher in the cisplatin-resistant group than in the cisplatin-sensitive group (P < 0.05). The monthly CA125 values of 40 patients were obtained after chemotherapy. In the cisplatin-sensitive group, 18 of the 24 cases exhibited normal CA125 values for more than one year, and the remaining 6 cases maintained normal values for more than half a year. In the cisplatin-resistant group, 16 cases revealed higher than normal CA125 values for half a year after chemotherapy. Recurrent lesions were observed in their color Doppler ultrasound results or MRI scans.
      Conclusion  Cisplatin resistance in ovarian cancer is strongly correlated with the expressions of IGF1, IGF1R and AKT. IGF1 is a potential candidate for the targeted therapy of ovarian cancer.

     

    • HTML全文
    • 参考文献(15)
    • 相关文章
    • 施引文献
  • 资源附件(0)

/

返回文章
返回